NEW YORK (BUSINESS WIRE) Forest Laboratories, Inc (NYSE: FRX) today announced that they will present data related to aclidinium bromide and roflumilast at the American Thoracic Society (ATS) International Conference on May 17 22 in Philadelphia, PA. Seven posters, two poster discussion sessions and one late breaking abstract will be presented for aclidinium bromide. Roflumilast related data will be highlighted in four posters and three poster discussion sessions.
During the ATS session titled “Pharmacological Treatment of COPD: New Developments” on Monday, May 20th from 8:15 am 10:45 am, the following three poster discussion sessions will take place:
“Aclidinium Bromide Improves Static Lung Function and Hyperinflation in Patients with Moderate-to-Severe COPD”
“Aclidinium Bromide Improves Exercise Endurance and Dynamic Hyperinflation and Decreases Exertional Dyspnoea in Patients with Moderate-to-Severe COPD”
“Roflumilast Prevents Cigarette Smoke-Induced Airway Surface Liquid Volume Depletion in Primary Human Bronchial Epithelia Cultures”
“Comparison of Physician-Reported, Spirometry-Based And Risk Plus Symptoms Classification Systems Within a US Sample of Severe/Very Severe COPD Patients”
“Alignment of Current Treatment Patterns for Severe/Very Severe COPD Patients with Updated GOLD Recommendations: Results from a Nationally Representative Patient Survey and Chart Review”